Bridging therapy and oral anticoagulation: Current and future prospects

Current Opinion in Hematology

Volumn 17, Issue 5, 2010, Pages 444-449

  Spyropoulos, Alex C ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

bridging therapy; low molecular weight heparin; oral anticoagulation; periprocedural management; unfractionated heparin

Indexed keywords

ACENOCOUMAROL; ANTIVITAMIN K; ARDEPARIN; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; FLUINDIONE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL; COST CONTROL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD LOSS, SURGICAL; DRUG ADMINISTRATION SCHEDULE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREOPERATIVE CARE; VITAMIN K; WARFARIN;

EID: 77955918007     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833c077b     Document Type: Review

References (44)

1. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119 (1 Suppl):176S-193S.
2. Jaffer AK, Brotman DJ, Chukwumerije N. When patients on warfarin need surgery. Cleve Clin J Med 2003; 70:973-984.
3. Spyropoulos AC. To bridge or not to bridge: that is the question. The argument FOR bridging therapy in patients on oral anticoagulants requiring temporary interruption for elective procedures. J Thromb Thrombolysis 2010; 29:192-198.
4. Douketis JD. Perioperative management of warfarin therapy: to bridge or not to bridge, that is the question. Mayo Clin Proc 2008; 83:628-629.
5. Jaffer AK. Perioperative management of warfarin and antiplatelet therapy. Cleve Clin J Med 2009; 76 (Suppl 4):S37-S44.
6. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (6 Suppl): 299S-339S.
7. Spyropoulos AC, Douketis JD. Guidelines for antithrombotic therapy: peri-procedural management of antithrombotic therapy and use of bridging anticoagulation. Int Angiol 2008; 27:333-343.
8. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89:635-641.
9. Kaatz S, Douketis JD, Zhou H, et al. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 2010; 8:884-890.
10. Spyropoulos AC. Bridging of oral anticoagulation therapy for invasive procedures. Curr Hematol Rep 2005; 4:405-413.
11. Thachil J, Gatt A, Martlew V. Management of surgical patients receiving anticoagulation and antiplatelet agents. Br J Surg 2008; 95:1437-1448.
12. Witt DM, Delate T, McCool KH, et al. Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anti-coagulation therapy. J Thromb Haemost 2009; 7:1982-1989.
13. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001; 119 (1 Suppl):22S-38S.
14. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA 1978; 239:738-739.
15. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995; 122:40-42.
16. Hewitt RL, Chun KL, Flint LM. Current clinical concepts in perioperative anticoagulation. Am Surg 1999; 65:270-273.
17. Eckman MH, Beshansky JR, Durand-Zaleski I, et al. Anticoagulation for noncardiac procedures in patients with prosthetic heart valves. Does low risk mean high cost? JAMA 1990; 263:1513-1521.
18. Katholi RE, Nolan SP, McGuire LB. Living with prosthetic heart valves. Subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 1976; 92:162-167.
19. Douketis JD, Crowther MA, Cherian SS. Perioperative anticoagulation in patients with chronic atrial fibrillation who are undergoing elective surgery: results of a physician survey. Can J Cardiol 2000; 16:326-330.
20. Douketis JD, Crowther MA, Cherian SS, Kearon CB. Physician preferences for perioperative anticoagulation in patients with a mechanical heart valve who are undergoing elective noncardiac surgery. Chest 1999; 116:1240-1246.
21. Jaff MR. Chronically anticoagulated' patients who need surgery: can low-molecular-weight heparins really be used to "bridge" patients instead of intravenous unfractionated heparin? Catheter Cardiovasc Interv 2009; 74 (Suppl 1):S17-S21.
22. Jaffer AK, Ahmed M, Brotman DJ, et al. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. J Thromb Thrombolysis 2005; 20:11-16.
23. Spyropoulos AC, Frost FJ, Hurley JS, Roberts M. Costs and clinical outcomes associated with low-molecular-weight heparin vs. unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004; 125:1642-1650.
24. Spyropoulos AC, Turpie AG, Dunn AS, et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol 2008; 102:883-889.
25. Spyropoulos AC, Turpie AG, Dunn AS, et al. Clinical outcomes with un-fractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006; 4:1246-1252.
26. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164:1319-1326.
27. Kovacs MJ, Kearon C, Rodger M, et al. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110:1658-1663.
28. Wysokinski WE, McBane RD, Daniels PR, et al. Periprocedural anticoagula tion management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 2008; 83:639-645.
29. Pengo V, Cucchini U, Denas G, et al. Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009; 119:2920-2927.
30. Malato A, Saccullo G, Lo Coco L, et al. Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin. J Thromb Haemost 2010; 8:107-113.
31. Giudici MC, Paul DL, Bontu P, Barold SS. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. Pacing Clin Electrophysiol 2004; 27:358-360.
32. University of Ottawa Heart Institute. Bridge or continue coumadin for device surgery randomized controlled trial (BRUISECONTROL). ClinicalTrialsgov Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrialsgov/ct2/show/NCT00800137?term1/4;NCT00800137&rank1/4;1 NLM Identifier: NCT00800137. [Accessed 20 January 2010]
33. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008; 168:63-69.
34. O'Donnell MJ, Kearon C, Johnson J, et al. Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 2007; 146:184-187.
35. National Heart, Lung and Blood Institute. Effectiveness of bridging anticoagulation for surgery (The BRIDGE Study). ClinicalTrialsgov Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/ ct2/show/NCT00786474?term1/4;NCT00786474&rank1/4;1 NLM Identifier: NCT00786474. [Accessed 20 January 2010]
36. Lawson Health Research Institute. PERIOP 2-a safety and effectiveness study of LMWH bridging therapy versus placebo bridging therapy for patients on long term warfarin and require temporary interruption of their warfarin. ClinicalTrialsgov Bethesda (MD): National Library of Medicine (US). Available from: http://clinicaltrials.gov/ct2/show/NCT00432796?term1/4; NCT00432796&rank1/4;1 NLM Identifier: NCT00432796. [Accessed 21 January 2010]
37. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115:15-20.
38. Sobieraj-Teague M, O'Donnell M, Eikelboom J. New anticoagulants for atrial fibrillation. Semin Thromb Hemost 2009; 35:515-524.
39. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139-1151.
40. Bayer. Randomized, double-blind study comparing once daily oral rivar-oxaban with adjusted-dose oral warfarin for the prevention of stroke in subjects with nonvalvular atrial fibrillation. ClinicalTrialsgov Bethesda (MD): National Library of Medicine (US) Available from: http://clinicaltrials. gov/ct2/show/NCT00403767?term1/4;NCT00403767&rank1/4;1 NLM Identifier: NCT00403767. [Accessed 11 January 2009]
41. Sinnaeve PR, Van de Werf FJ. Will oral antithrombin agents replace warfarin? Heart 2004; 90:827-828.
42. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64:292-303.
43. Mismetti P, Laporte S. Rivaroxaban: clinical pharmacology. Ann Fr Anesth Reanim 2008; 27 (Suppl 3):S16-S21.
44. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49:259-268.